Important insights for non-molar choriocarcinoma

N S Horowitz^{1

2

3}, R S Berkowitz^{1

2

3}, K M Elias^{1

2

3}

Affiliations

¹ New England Trophoblastic Disease Center, Brigham and Women's Hospital, Boston, Massachusetts, USA.
² Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
³ Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.

Comment

N S Horowitz et al. BJOG. 2020 Aug.

. 2020 Aug;127(9):1108.

doi: 10.1111/1471-0528.16235. Epub 2020 Apr 17.

N S Horowitz^{1

2

3}, R S Berkowitz^{1

2

3}, K M Elias^{1

2

3}

¹ New England Trophoblastic Disease Center, Brigham and Women's Hospital, Boston, Massachusetts, USA.
² Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
³ Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.

No abstract available

Comment on

Demographics, natural history and treatment outcomes of non-molar gestational choriocarcinoma: a UK population study.
Savage P, Winter M, Parker V, Harding V, Sita-Lumsden A, Fisher RA, Harvey R, Unsworth N, Sarwar N, Short D, Aguiar X, Tidy J, Hancock B, Coleman R, Seckl MJ. Savage P, et al. BJOG. 2020 Aug;127(9):1102-1107. doi: 10.1111/1471-0528.16202. Epub 2020 Apr 3. BJOG. 2020. PMID: 32146729